CABALETTA BIO INC. - COMMON STOCK

Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis

06 11 2023 06:00:00 提供 Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

30 10 2023 07:00:00 提供 Nasdaq GlobeNewswire

Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201

02 10 2023 06:00:00 提供 Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

19 9 2023 07:00:00 提供 Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

30 8 2023 07:00:00 提供 Nasdaq GlobeNewswire

Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201

22 8 2023 07:00:00 提供 Nasdaq GlobeNewswire

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

10 8 2023 06:00:01 提供 Nasdaq GlobeNewswire

Cabaletta Bio to Present at the Jefferies Healthcare Conference

31 5 2023 07:00:00 提供 Nasdaq GlobeNewswire

Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

22 5 2023 15:30:00 提供 Nasdaq GlobeNewswire

Cabaletta Bio Announces Pricing of Public Offering of Common Stock

17 5 2023 21:16:01 提供 Nasdaq GlobeNewswire

Cabaletta Bio Announces Proposed Public Offering of Common Stock

17 5 2023 15:01:00 提供 Nasdaq GlobeNewswire

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis

16 5 2023 06:00:00 提供 Nasdaq GlobeNewswire

Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update

11 5 2023 06:00:01 提供 Nasdaq GlobeNewswire

Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting

02 5 2023 15:35:00 提供 Nasdaq GlobeNewswire

Cabaletta Bio Receives FDA Fast Track Designation for CABA-201

01 5 2023 06:00:00 提供 Nasdaq GlobeNewswire

Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

25 4 2023 07:00:01 提供 Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference

13 4 2023 15:30:00 提供 Nasdaq GlobeNewswire

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus

31 3 2023 06:00:00 提供 Nasdaq GlobeNewswire

Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

16 3 2023 06:00:01 提供 Nasdaq GlobeNewswire

Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference

28 2 2023 07:00:02 提供 Nasdaq GlobeNewswire